The Sydney / New South Wales Market
Sydney and New South Wales is Australia's primary market for Pharmaceuticals & Life Sciences — and the regulatory environment combines federal Australian frameworks with NSW-specific requirements that most national vendors address inadequately. OAIC Privacy Act enforcement, APRA prudential standards (where applicable), and NSW sector-specific legislation create a compliance surface area that exceeds what generic 'Australia compliance' covers.
Pharmaceuticals & Life Sciences organizations in Sydney operate under active OAIC, ACCC, and APRA enforcement — regulators that have demonstrated willingness to pursue technology failures in regulated industries. Engineering teams serving this market need Australian compliance architecture built for the enforcement environment, not the documentation standard.
Compliance Coverage
Every system we deploy for Pharmaceuticals & Life Sciences in Sydney / New South Wales is FDA 21 CFR Part 11-compliant from architecture through deployment. FDA 21 CFR Part 11 and HIPAA compliance is enforced automatically at every commit — not assessed after the fact.
Engagement Scope
Duration: 8–16 weeks
A focused team deployed against a single Pharmaceuticals & Life Sciences platform in Sydney / New South Wales. FDA 21 CFR Part 11 and HIPAA-compliant architecture from day one. Fixed price, fixed output, no discovery phase.
Duration: 3–9 months
40–100 engineers running parallel workstreams across a Pharmaceuticals & Life Sciences transformation in Sydney / New South Wales. Multi-system compliance governance and FDA 21 CFR Part 11 and HIPAA certification maintained across the full program.
Duration: 6–18 months
100–250+ engineers owning the complete technology infrastructure for a Pharmaceuticals & Life Sciences organization in Sydney / New South Wales. Full FDA 21 CFR Part 11 and HIPAA compliance across every system, every integration, every deployment.